Navamedic Takes Over Marketing of Glucomed in Sweden, Denmark, Norway and Finland

January 24, 2008- Through its subsidiary Vitaflo Scandinavia AB, Navamedic will take responsibility for the marketing and distribution of Glucomed in Sweden, Denmark, Norway and Finland

Vitaflo has for several years shown a good track record for marketing of pharmaceutical products in the Nordic countries. Through Vitaflo, the company strongly believes that it is in position to take a larger part of the Nordic market for glucosamine products. The change will strengthen Navamedic's position within marketing and distribution of pharmaceuticals in the region, and the change will give a higher gross margin on future sales of Glucomed in these countries.

The change is initiated by Navamedic, as a result of Meda's acquisition of the pharmaceutical company Recip towards the end of 2007. Meda thus became the owner of Glucosine, one of Glucomed's competitors in some of the Nordic markets. The change will be effective from 1 March 2008.

In Q4 2007, Navamedic will state as income the rest of a provision related to a possible regulation of prices on earlier sales of Glucomed to Meda. In Q1 2008, the remaining provisions related to the received license income will be stated as income.